Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial

Sirichai Wiriyatanakorn; Somnuek Sungkanuparph

doi:10.1093/ofid/ofz297

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial

Sirichai Wiriyatanakorn
, Somnuek Sungkanuparph

Chakri Naruebodindra Medical Institute

Faculty of Medicine Ramathibodi Hospital, Mahidol University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.

Original language	English
Article number	ofz297
Journal	Open Forum Infectious Diseases
Volume	6
Issue number	7
DOIs	https://doi.org/10.1093/ofid/ofz297
Publication status	Published - 1 Jul 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antiretroviral therapy
efavirenz
randomized controlled trial
rilpivirine
switching

Access to Document

10.1093/ofid/ofz297

Cite this

@article{f24513e86bb54f89afb08609454d76d6,

title = "Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial",

abstract = "A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.",

keywords = "antiretroviral therapy, efavirenz, randomized controlled trial, rilpivirine, switching",

author = "Sirichai Wiriyatanakorn and Somnuek Sungkanuparph",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/ofid/ofz297",

language = "English",

volume = "6",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "7",

}

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial. / Wiriyatanakorn, Sirichai; Sungkanuparph, Somnuek.
In: Open Forum Infectious Diseases, Vol. 6, No. 7, ofz297, 01.07.2019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression

T2 - A Randomized Controlled Trial

AU - Wiriyatanakorn, Sirichai

AU - Sungkanuparph, Somnuek

PY - 2019/7/1

Y1 - 2019/7/1

N2 - A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.

AB - A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.

KW - antiretroviral therapy

KW - efavirenz

KW - randomized controlled trial

KW - rilpivirine

KW - switching

UR - https://www.scopus.com/pages/publications/85084486006

U2 - 10.1093/ofid/ofz297

DO - 10.1093/ofid/ofz297

M3 - Article

AN - SCOPUS:85084486006

SN - 2328-8957

VL - 6

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 7

M1 - ofz297

ER -

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this